Akari Therapeutics director exercises warrants
The RSU and option awards are subject to forfeiture if shareholder approval of the proposed plan amendment is not obtained.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Akari Therapeutics Plc director Robert B. Bazemore reported exercising pre-funded warrants for 773 and 3,093 ADSs on October 14, 2026, acquiring corresponding American Depositary Shares at an exercise price of $0.0004 per ADS; the related warrant positions were reported as disposed. The warrants became exercisable upon shareholder approval obtained March 2, 2026.
He also received awards of 13,100 ADSs representing restricted stock units on August 18, 2026, and 4,677 ADSs representing restricted stock units on October 5, 2026. The RSUs were granted in lieu of accrued but unpaid cash retainers in accordance with the Company's remuneration policy. They will vest in full upon shareholder approval of a proposed equity incentive plan amendment and are subject to forfeiture if approval is not obtained. On August 18, 2026, he also received options to purchase 45,000 and 15,000 ADSs, each with a $7.899 exercise price and an August 18, 2036 expiration date; those options are also subject to forfeiture if approval is not obtained.
Insider Trade Summary
3,866 shares exercised/converted
Exercise
8 txns
Insider
Bazemore Robert B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Pre-Funded Warrant to Purchase ADSs F8, F10, F6, F7 | 773 | $16.16 | $12K |
| Exercise | Pre-Funded Warrant to Purchase ADSs F9, F10, F6, F7 | 3,093 | $16.16 | $50K |
| Exercise | American Depositary Shares representing Ordinary Shares | 773 | $0.0004 | $0.31 |
| Exercise | American Depositary Shares representing Ordinary Shares | 3,093 | $0.0004 | $1.24 |
| Grant/Award | American Depositary Shares representing Ordinary Shares F2, F3 | 4,677 | $7.899 | $37K |
| Grant/Award | Stock Option (Right to Buy) F4 | 45,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F5 | 15,000 | $0.00 | $0.00 |
| Grant/Award | American Depositary Shares representing Ordinary Shares F1, F3 | 13,100 | $7.899 | $103K |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Pre-Funded Warrant to Purchase ADSs — 0 contracts (Direct);
American Depositary Shares representing Ordinary Shares — 22,759 shares (Direct)
Footnotes (10)
- F1. These American Depositary Shares ("ADSs") represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on August 18, 2026, and is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. The RSUs will vest in full on the date of Shareholder Approval.
- F2. These ADSs represent RSUs, with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on October 5 2026, and is subject to forfeiture if Shareholder Approval is not obtained. The RSUs will vest in full on the date of Shareholder Approval.
- F3. This award of RSUs was granted in lieu of accrued but unpaid cash retainers payable to non-execute directors in accordance with the Company's remuneration policy.
- F4. On August 18, 2026, the Reporting Person was granted an option to purchase 45,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with respect to 33% of the grant on the date of Shareholder Approval plus 2.91% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the two-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- F5. On August 18, 2026, the Reporting Person was granted an option to purchase 15,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 8.33% of the grant on the date of Shareholder Approval plus 8.33% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the one-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- F6. The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
- F7. The pre-funded warrants remain exercisable until fully exercised.
- F8. On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 773 ADSs.
- F9. On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Private Placement Pre-Funded Warrants") to purchase up to 3,093 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 3,093 ADSs.
- F10. The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.
Key Figures
ADSs acquired upon warrant exercise: 773 ADSs
ADSs acquired upon warrant exercise: 3,093 ADSs
Warrant exercise price: $0.0004 per ADS
+5 more
8 metrics
ADSs acquired upon warrant exercise
773 ADSs
October 14, 2026
ADSs acquired upon warrant exercise
3,093 ADSs
October 14, 2026
Warrant exercise price
$0.0004 per ADS
October 14, 2026
RSU award
13,100 ADSs
August 18, 2026
RSU award
4,677 ADSs
October 5, 2026
Options granted
45,000 ADSs
August 18, 2026
Options granted
15,000 ADSs
August 18, 2026
Option exercise price
$7.899 per ADS
Options granted August 18, 2026
Key Terms
pre-funded warrants, restricted stock units (RSUs), Shareholder Approval, vest
4 terms
pre-funded warrants financial
"The pre-funded warrants became exercisable upon shareholder approval"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
restricted stock units (RSUs) financial
"These ADSs represent restricted stock units ("RSUs")"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
vest financial
"The RSUs will vest in full on the date of Shareholder Approval"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AKTX ADSs did Robert B. Bazemore acquire through pre-funded warrant exercises?
He acquired 773 ADSs and 3,093 ADSs on October 14, 2026, through exercise of the corresponding pre-funded warrants, at an exercise price of $0.0004 per ADS.
What approval conditions apply to Robert B. Bazemore's AKTX RSU and option awards?
The RSUs and options are subject to forfeiture if shareholder approval of the proposed amendment to the equity incentive plan is not obtained. The RSUs vest in full on the date of that approval. Option vesting is scheduled in installments and is subject to continued service on each applicable vesting date.
When did AKTX's pre-funded warrants become exercisable?
The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. They remain exercisable until fully exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
